Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Mice, Transgenic

This is a "connection" page, showing publications Vernon Holers has written about Mice, Transgenic.

 
Connection Strength
 
 
 
0.507
 
  1. Cordova KN, Willis VC, Haskins K, Holers VM. A citrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. J Immunol. 2013 Feb 15; 190(4):1457-65.
    View in: PubMed
    Score: 0.069
  2. Kulik L, Chen K, Huber BT, Holers VM. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol Immunol. 2011 Mar; 48(6-7):883-94.
    View in: PubMed
    Score: 0.061
  3. Kulik L, Marchbank KJ, Lyubchenko T, Kuhn KA, Liubchenko GA, Haluszczak C, Gipson MG, Gibson MG, Boackle SA, Holers VM. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur J Immunol. 2007 Mar; 37(3):623-33.
    View in: PubMed
    Score: 0.046
  4. Kang HJ, Bao L, Xu Y, Quigg RJ, Giclas PC, Holers VM. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects. Clin Exp Immunol. 2004 May; 136(2):194-9.
    View in: PubMed
    Score: 0.038
  5. Marchbank KJ, Kulik L, Gipson MG, Morgan BP, Holers VM. Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia. J Immunol. 2002 Oct 01; 169(7):3526-35.
    View in: PubMed
    Score: 0.034
  6. Makar KW, Ulgiati D, Hagman J, Holers VM. A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. Int Immunol. 2001 May; 13(5):657-64.
    View in: PubMed
    Score: 0.031
  7. Marchbank KJ, Watson CC, Ritsema DF, Holers VM. Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function. J Immunol. 2000 Sep 01; 165(5):2354-61.
    View in: PubMed
    Score: 0.029
  8. Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med. 1998 Oct 05; 188(7):1321-31.
    View in: PubMed
    Score: 0.026
  9. Makar KW, Pham CT, Dehoff MH, O'Connor SM, Jacobi SM, Holers VM. An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. J Immunol. 1998 Feb 01; 160(3):1268-78.
    View in: PubMed
    Score: 0.025
  10. Holers VM, Hollis GF, Schwartz BD, Evans RJ, Strauss-Schoenberger J, Carel JC, Barney DL, Li B, Stafford-Hollis J, Lacy PE. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen. A multi-stage model of disease. J Immunol. 1993 Nov 01; 151(9):5041-52.
    View in: PubMed
    Score: 0.018
  11. Pappworth IY, Hayes C, Dimmick J, Morgan BP, Holers VM, Marchbank KJ. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology. 2012 Feb; 217(2):147-57.
    View in: PubMed
    Score: 0.016
  12. Twohig JP, Pappworth IY, Sivasankar B, Kulik L, Bull M, Holers VM, Wang EC, Marchbank KJ. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol Immunol. 2009 Jun; 46(10):2002-13.
    View in: PubMed
    Score: 0.013
  13. Pappworth IY, Kulik L, Haluszczak C, Reuter JW, Holers VM, Marchbank KJ. Increased B cell deletion and significantly reduced auto-antibody titre due to premature expression of human complement receptor 2 (CR2, CD21). Mol Immunol. 2009 Mar; 46(6):1042-9.
    View in: PubMed
    Score: 0.013
  14. Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007 Jul; 44(13):3434-44.
    View in: PubMed
    Score: 0.012
  15. Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, Quax PH. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation. 2006 Dec 19; 114(25):2831-8.
    View in: PubMed
    Score: 0.011
  16. Birrell L, Kulik L, Morgan BP, Holers VM, Marchbank KJ. B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens. J Immunol. 2005 Jun 01; 174(11):6974-82.
    View in: PubMed
    Score: 0.010
  17. M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
    View in: PubMed
    Score: 0.009
  18. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J Immunol. 2003 Aug 15; 171(4):2109-15.
    View in: PubMed
    Score: 0.009
  19. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
    View in: PubMed
    Score: 0.008
  20. Park P, Haas M, Cunningham PN, Alexander JJ, Bao L, Guthridge JM, Kraus DM, Holers VM, Quigg RJ. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol. 2001 Jul; 12(7):1383-1390.
    View in: PubMed
    Score: 0.008
  21. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol. 2001 Jan; 12(1):71-79.
    View in: PubMed
    Score: 0.008
  22. Alexander JJ, Lim A, He C, MacDonald RL, Holers VM, Quigg RJ. Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury. Immunopharmacology. 1999 May; 42(1-3):245-54.
    View in: PubMed
    Score: 0.007
  23. Kearns-Jonker M, Monell-Torrens E, Abbasi F, Holers VM, Notkins AL, Sigounas G. EBV binds to lymphocytes of transgenic mice that express the human CR2 gene. Virus Res. 1997 Jul; 50(1):85-94.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)